Albert Tran
YOU?
Author Swipe
View article: Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD
Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD Open
Background and Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatocellular carcinoma (HCC), particularly in obesity. Mixed Lineage Kinase Domain Like (MLKL), the effector of proinflammatory ce…
View article: <scp>CD44</scp> in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis
<span>CD44</span> in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis Open
Background and Aims Innate lymphoid cells (ILCs) play pivotal roles in inflammation and fibrosis, which are key features of chronic liver diseases. The contribution of group 1 ILCs, including natural killer (NK) cells and helper‐like ILC1s…
View article: 708. COMPARISON OF FEATURES OF RELAPSE RISK BETWEEN ALCOHOL-DEPENDENT INDIVIDUALS IN JAPAN AND AUSTRALIA THROUGH USE OF VALIDATED SELF-RATING SCALE: THE ALCOHOL RELAPSE RISK SCALE
708. COMPARISON OF FEATURES OF RELAPSE RISK BETWEEN ALCOHOL-DEPENDENT INDIVIDUALS IN JAPAN AND AUSTRALIA THROUGH USE OF VALIDATED SELF-RATING SCALE: THE ALCOHOL RELAPSE RISK SCALE Open
Background Alcohol use disorder (AUD) is a prevalent, chronic condition with potential serious consequences. The Alcohol Relapse Risk Scale (ARRS) is a multi-dimensional, 32-item self-reported scale developed in Japan which has shown corre…
View article: 407. COMPARISON OF FEATURES OF RELAPSE RISK BETWEEN ALCOHOL-DEPENDENT INDIVIDUALS IN JAPAN AND AUSTRALIA THROUGH USE OF VALIDATED SELF-RATING SCALE: THE ALCOHOL RELAPSE RISK SCALE
407. COMPARISON OF FEATURES OF RELAPSE RISK BETWEEN ALCOHOL-DEPENDENT INDIVIDUALS IN JAPAN AND AUSTRALIA THROUGH USE OF VALIDATED SELF-RATING SCALE: THE ALCOHOL RELAPSE RISK SCALE Open
Background Alcohol use disorder (AUD) is a prevalent, chronic condition with potential serious consequences. The Alcohol Relapse Risk Scale (ARRS) is a multi-dimensional, 32-item self-reported scale developed in Japan which has shown corre…
View article: Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders Open
View article: A Non-canonical Role for Hepatocyte MLKL in Promoting Mitochondrial Dysfunction and Senescence in the Aging Liver
A Non-canonical Role for Hepatocyte MLKL in Promoting Mitochondrial Dysfunction and Senescence in the Aging Liver Open
Liver aging is characterized by chronic inflammation and metabolic dysfunction that contributes to the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Necroptosis, a form of inflammatory cell death, is acti…
View article: Impact of Mlkl or Ripk3 deletion on age-associated liver inflammation, metabolic health, and lifespan
Impact of Mlkl or Ripk3 deletion on age-associated liver inflammation, metabolic health, and lifespan Open
View article: CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease Open
Background and Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immun…
View article: From severe acute cholangitis to aggressive intrahepatic cholangiocarcinoma: Causal or coincidental association?
From severe acute cholangitis to aggressive intrahepatic cholangiocarcinoma: Causal or coincidental association? Open
View article: Robust Optical Clocks for International Timescales (ROCIT)
Robust Optical Clocks for International Timescales (ROCIT) Open
The recently concluded collaborative European project “Robust optical clocks for international timescales” (ROCIT) tackled some of the key challenges on the roadmap towards a redefinition of the SI second. This paper gives an overview of p…
View article: Enhanced liver fibrosis score is stable after withdrawal in patients with heavy alcohol consumption: A pilot study
Enhanced liver fibrosis score is stable after withdrawal in patients with heavy alcohol consumption: A pilot study Open
Background Enhanced liver fibrosis (ELF) score is an accurate, noninvasive test for assessing the severity of liver fibrosis in chronic liver disease, including alcohol‐related liver disease. However, whether the ELF score changes during a…
View article: Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort Open
Bulevirtide is the only EMA-approved drug for HDV treatment, and we showed that it can be used in adults living with HIV, with an overall good tolerability. Bulevirtide induces a virological response in more than 50% of patients, suggestin…
View article: Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High-Fat, High-Fructose, High-Cholesterol Diet Mouse Model
Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High-Fat, High-Fructose, High-Cholesterol Diet Mouse Model Open
Chronic inflammation is a key player in metabolic dysfunction-associated fatty liver disease (MAFLD) progression. Necroptosis, an inflammatory cell death pathway, is elevated in MAFLD patients and mouse models, yet its role is unclear due …
View article: Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High Fat, High Fructose, High Cholesterol Diet Mouse Model
Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High Fat, High Fructose, High Cholesterol Diet Mouse Model Open
Chronic inflammation is a key player in metabolic dysfunction-associated fatty liver disease (MAFLD) progression. Necroptosis, an inflammatory cell death pathway, is elevated in MAFLD patients and mouse models, yet its role is unclear due …
View article: Osteopontin‐driven T‐cell accumulation and function in adipose tissue and liver promoted insulin resistance and <scp>MAFLD</scp>
Osteopontin‐driven T‐cell accumulation and function in adipose tissue and liver promoted insulin resistance and <span>MAFLD</span> Open
Objective This study investigated the contribution of osteopontin/secreted phosphoprotein 1 (SPP1) to T‐cell regulation in initiation of obesity‐driven adipose tissue (AT) inflammation and macrophage infiltration and the subsequent impact …
View article: Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort)
Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort) Open
View article: Supplementary Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supplementary Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Supplementary Data_Clean File
View article: Supplementary Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supplementary Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Supplementary Data_Clean File
View article: Supp Figure S1 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S1 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S1. Forest plots of overall survival and progression-free survival by baseline AFP. Hazard ratios are stratified for the overall study population and unstratified for the subgroups.
View article: Supp Figure S4 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S4 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S4. Percent change in target lesion sum of diameters from baseline at Week 8 versus percent change in AFP from baseline at Week 8 in the cabozantinib group (N=228 evaluable patients) and the placebo group (N=109 evaluable patients).
View article: Supp Figure S3 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S3 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S3. AFP response cutoff determination for overall survival by maximally selected rank statistics. Cutpoint determination plots showing (A) histogram distribution and (B) rank statistic plot of percent AFP change from baseline at Wee…
View article: Supp Figure S2 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S2 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S2. Forest plots of overall survival and progression-free survival by AFP control/response/progression in the cabozantinib group.
View article: Supp Figure S1 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S1 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S1. Forest plots of overall survival and progression-free survival by baseline AFP. Hazard ratios are stratified for the overall study population and unstratified for the subgroups.
View article: Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Purpose:The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyze…
View article: Supp Figure S4 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S4 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S4. Percent change in target lesion sum of diameters from baseline at Week 8 versus percent change in AFP from baseline at Week 8 in the cabozantinib group (N=228 evaluable patients) and the placebo group (N=109 evaluable patients).
View article: Supp Figure S2 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S2 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S2. Forest plots of overall survival and progression-free survival by AFP control/response/progression in the cabozantinib group.
View article: Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Purpose:The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyze…
View article: Supp Figure S3 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Supp Figure S3 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Open
Figure S3. AFP response cutoff determination for overall survival by maximally selected rank statistics. Cutpoint determination plots showing (A) histogram distribution and (B) rank statistic plot of percent AFP change from baseline at Wee…
View article: Mid-Infrared Spectroscopy as a New Tool for Ruling Out Spontaneous Bacterial Peritonitis: A Proof-of-Concept Study
Mid-Infrared Spectroscopy as a New Tool for Ruling Out Spontaneous Bacterial Peritonitis: A Proof-of-Concept Study Open
Background and aims: A highly sensitive and specific point-of-care method for diagnosing spontaneous bacterial peritonitis (SBP) is currently lacking. The objective of the present study is to evaluate the diagnostic value of a rapid, easy-…
View article: Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial Open